CALM: A retrospective registry to characterize clinical outcome data for chronic non-infectious posterior segment uveitis patients treated with a 0.18 mg fluocinolone acetonide intravitreal insert

被引：0

作者：

Seth, Kanika ^{[1
]}

Singh, Rishi P. ^{[1
]}

Sharma, Sumit ^{[1
]}

机构：

[1] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA

来源：

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2022年 / 63卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

3205-A043

引用

页数：3

共 49 条

[1] CALM: A retrospective registry to characterize clinical outcomes for chronic non-infectious posterior segment uveitis patients treated with the 0.18 mg fluocinolone acetonide intravitreal insert: Intraocular Pressure and Safety Data Analysis
Seth, Kanika
Zhao, Alison
Singh, Rishi
Sharma, Sumit
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
[2] CALM: A retrospective registry to characterize clinical outcomes for chronic non-infectious posterior segment uveitis patients treated with the 0.18 mg fluocinolone acetonide intravitreal implant: Retinal Anatomical Outcomes
Zhao, Alison
Seth, Kanika
Bena, James
Morrison, Shannon
Singh, Rishi
Sharma, Sumit
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
[3] CALM: 12-month results from a real-world registry to characterize clinical outcomes for patients with chronic non-infectious posterior segment uveitis treated with a 0.18 mg fluocinolone acetonide intravitreal insert
Anesi, Stephen
Chang, Peter
Singh, Rishi
Sharma, Sumit
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
[4] CALM: 24-month safety outcomes from a real-world registry study of patients with chronic non-infectious uveitis affecting the posterior segment treated with the 0.18 mg fluocinolone acetonide intravitreal implant
Begaj, Tedi
Faia, Lisa
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
[5] CALM: 24-month retinal thickness outcomes from a real-world registry study of patients with chronic non-infectious uveitis affecting the posterior segment treated with the 0.18 mg fluocinolone acetonide intravitreal implant
Lin, Phoebe
Suhler, Eric B.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
[6] Controlling Posterior Segment Uveitic Recurrences: Results from a Phase 3 Study of 0.18 mg Fluocinolone Acetonide Intravitreal Insert (FAi) in Subjects with Chronic Non-Infectious Uveitis Affecting the Posterior Segment
Quan Dong Nguyen
Patel, Keyur
Paggiarino, Dario A.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
[7] Fluocinolone Acetonide Intravitreal Implant (Retisert) for Non-Infectious Posterior Uveitis
Timoney, P.
Pearson, P. A.
IRISH JOURNAL OF MEDICAL SCIENCE, 2015, 184 : 466 - 466
[8] Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis
Hikal, Muaas
Celik, Nil
Auffarth, Gerd Uwe
Kessler, Lucy Joanne
Mayer, Christian Steffen
Khoramnia, Ramin
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (17)
[9] Safety and Efficacy of an intravitreal 0.18 mg fluocinolone acetonide insert (FAi) for the treatment of non-infectious posterior segment uveitis (NIPU) - pooled results of two phase 3 trials
Suhler, Eric B.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
[10] An Injectable Fluocinolone Acetonide Intravitreal Insert Decreases the Incidence of Recurrence in Patients with Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye: 12 Month Results
Jaffe, Glenn J.
Paggiarino, Dario
Riedel, Gerald
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)

← 1 2 3 4 5 →